Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia".
Damian LaiMin ChenJiechuang SuXiaohu LiuKatharina RotheKaiji HuDonna L ForrestConnie J EavesGregg B MorinXiaoyan JiangPublished in: Science translational medicine (2020)
LB100 sensitizes resistant chronic phase CML stem and progenitor cells to TKIs and spares healthy bone marrow cells.